Market capitalization | $246.09m |
Enterprise Value | $170.29m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.33 |
P/S ratio (TTM) P/S ratio | 3.37 |
P/B ratio (TTM) P/B ratio | 2.19 |
Sales growth (TTM) Sales growth | 27.14% |
Turnover (TTM) Turnover | $72.99m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
6 Analysts have issued a ProLung Inc forecast:
6 Analysts have issued a ProLung Inc forecast:
Dec '23 |
+/-
%
|
||
Net profit | -61 -61 |
3%
3%
|
|
Depreciation and amortization | 1.95 1.95 |
51%
51%
|
|
Share compensation | 22 22 |
34%
34%
|
|
Operating cash flow | -38 -38 |
17%
17%
|
|
Investments | 0.81 0.81 |
39%
39%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -38 -38 |
17%
17%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Steven Williamson |
Employees | 279 |
Founded | 1995 |
Website | www.pulmonx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.